New PET tracer could spot organ damage in amyloidosis patients
NCT ID NCT05235269
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This phase 2 study tested a radioactive tracer called 124I-AT-01 in 33 people with systemic amyloidosis. The goal was to see how well PET/CT scans could measure amyloid buildup in organs like the heart and kidneys, and whether the results were consistent when repeated. The study focused on imaging accuracy, not treatment, and may lead to better ways to diagnose and monitor this rare disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Northern California PET Imaging Center
Sacramento, California, 95816, United States
-
PET/CT Imaging of Berkeley
Berkeley, California, 94705, United States
-
PET/CT Imaging of San Jose
San Jose, California, 95128, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
124I-AT-01 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors better detect and track amyloid buildup in organs, leading to earlier diagnosis and more precise monitoring of amyloidosis.
What could go wrong
This is a small, early-phase study focused on repeatability of imaging, not on treatment. It may not lead to widespread clinical use, and the tracer involves radiation exposure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.